140 related articles for article (PubMed ID: 30719210)
21. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Gründker C; Völker P; Emons G
Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
[TBL] [Abstract][Full Text] [Related]
22. LHRH receptor expression in sarcomas of bone and soft tissue.
Deivaraju C; Temple HT; Block N; Robinson P; Schally AV
Horm Mol Biol Clin Investig; 2016 Nov; 28(2):105-111. PubMed ID: 27639272
[TBL] [Abstract][Full Text] [Related]
23. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
[TBL] [Abstract][Full Text] [Related]
24. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors.
Leuschner C; Enright FM; Gawronska-Kozak B; Hansel W
Prostate; 2003 Sep; 56(4):239-49. PubMed ID: 12858351
[TBL] [Abstract][Full Text] [Related]
25. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
26. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
Irmer G; Bürger C; Müller R; Ortmann O; Peter U; Kakar SS; Neill JD; Schulz KD; Emons G
Cancer Res; 1995 Feb; 55(4):817-22. PubMed ID: 7850795
[TBL] [Abstract][Full Text] [Related]
27. Development of tumor-targeted near infrared probes for fluorescence guided surgery.
Kelderhouse LE; Chelvam V; Wayua C; Mahalingam S; Poh S; Kularatne SA; Low PS
Bioconjug Chem; 2013 Jun; 24(6):1075-80. PubMed ID: 23642154
[TBL] [Abstract][Full Text] [Related]
28. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
Srkalovic G; Bokser L; Radulovic S; Korkut E; Schally AV
Endocrinology; 1990 Dec; 127(6):3052-60. PubMed ID: 2174343
[TBL] [Abstract][Full Text] [Related]
29. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases.
Leuschner C; Kumar CS; Hansel W; Soboyejo W; Zhou J; Hormes J
Breast Cancer Res Treat; 2006 Sep; 99(2):163-76. PubMed ID: 16752077
[TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis, and Evaluation of a Neurokinin-1 Receptor-Targeted Near-IR Dye for Fluorescence-Guided Surgery of Neuroendocrine Cancers.
Kanduluru AK; Srinivasarao M; Low PS
Bioconjug Chem; 2016 Sep; 27(9):2157-65. PubMed ID: 27529726
[TBL] [Abstract][Full Text] [Related]
31. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
Kovacs M; Schally AV
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12197-202. PubMed ID: 11593037
[TBL] [Abstract][Full Text] [Related]
32. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers.
Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
Clin Cancer Res; 2001 Aug; 7(8):2340-3. PubMed ID: 11489810
[TBL] [Abstract][Full Text] [Related]
33. LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
Bioconjug Chem; 2008 Nov; 19(11):2156-62. PubMed ID: 18850733
[TBL] [Abstract][Full Text] [Related]
34. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.
Liu SV; Liu S; Pinski J
Expert Opin Investig Drugs; 2011 Jun; 20(6):769-78. PubMed ID: 21449823
[TBL] [Abstract][Full Text] [Related]
35. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
36. Single molecular recognition force spectroscopy study of a luteinizing hormone-releasing hormone analogue as a carcinoma target drug.
Zhang J; Wu G; Song C; Li Y; Qiao H; Zhu P; Hinterdorfer P; Zhang B; Tang J
J Phys Chem B; 2012 Nov; 116(45):13331-7. PubMed ID: 23094688
[TBL] [Abstract][Full Text] [Related]
37. A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer.
Zhu S; Wang Q; Jiang J; Luo Y; Sun Z
Sci Rep; 2016 Sep; 6():33894. PubMed ID: 27654169
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
39. Selective gene delivery to cancer cells using an integrated cationic amphiphilic peptide.
Tang Q; Cao B; Wu H; Cheng G
Langmuir; 2012 Nov; 28(46):16126-32. PubMed ID: 23088373
[TBL] [Abstract][Full Text] [Related]
40. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
Günthert AR; Gründker C; Böttcher B; Emons G
Anticancer Res; 2004; 24(3a):1727-32. PubMed ID: 15274347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
